NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistance The Phase 1 ragistomig study achieved its...
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide Strategy centers on broadening access to global capital and innovation through a planned Hong Kong...